Nexletol works by inhibiting cholesterol production. It can reduce LDL cholesterol by 28% the company said. The company has also applied for FDA approval to use the drug as a combination pill with ezetimibe, another non-statin. In studies, that combination reduced cholesterol between 38% to 44%, the company said. That FDA decision is expected soon.
Esperion, which is based in Ann Arbor, Mich., said the drug’s brand name will be Nexletol. Esperion also has applied to the FDA for approval of a combination pill of bempedoic acid and ezetimibe, a non-statin pill approved in 2002. In studies, the combination pill reduced cholesterol by about 38 to 44 percent, depending on whether a person was taking a statin and how much, the company said. The FDA decision is expected shortly.